Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Sangamo Therapeutics Inc (SGMO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Sangamo Therapeutics's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.5399 +0.0298    +5.84%
12:47:36 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 1,279,655
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.5100 - 0.5700
Sangamo Therapeutics 0.5399 +0.0298 +5.84%

NASDAQ:SGMO Financials

 
A brief overview of the NASDAQ:SGMO financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Sangamo over time.

Sangamo Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 9.4 million compared to USD 26.46 million a year ago. Net loss was USD 104.16 million compared to USD 53.16 million a year ago. Basic loss per share from continuing operations was USD 0.59 compared to USD 0.34 a year ago. Diluted loss per share from continuing operations was USD 0.59 compared to USD 0.34 a year ago.For the nine months, sales was USD 174.19 million compared to USD 84.07 million a year ago. Net loss was USD 197.54 million compared to USD 140.31 million a year ago. Basic loss per share from continuing operations was USD 1.14 compared to USD 0.93 a year ago. Diluted loss per share from continuing operations was USD 1.14 compared to USD 0.93 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

SGMO Income Statement

Gross margin TTM -25.72%
Operating margin TTM -58.16%
Net Profit margin TTM -146.3%
Return on Investment TTM -38.4%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 2.04 9.4 6.84 157.96
Gross Profit -40.26 -47.69 -56.21 94.74
Operating Income -50.56 -61.61 -72.22 76.6
Net Income -60.3 -104.16 -114.51 21.13

SGMO Balance Sheet

Quick Ratio MRQ 1.72
Current Ratio MRQ 1.98
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 45.97%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 165.32 219.7 325.07 440.57
Total Liabilities 82.43 84.78 91.43 104.96
Total Equity 82.89 134.92 233.64 335.61

SGMO Cash Flow Statement

Cash Flow/Share TTM -1.27
Revenue/Share TTM 0.99
Operating Cash Flow  -105.89%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -50.54 -47.29 -60.71 -66.3
Cash From Investing Activities 37.71 37.63 42.47 35.73
Cash From Financing Activities 0.167 -0.1 6.52 8
Net Change in Cash -11.31 -10.32 -11.41 -22.2
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SGMO Comments

Write your thoughts about Sangamo Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ace Geo
Ace Geo Apr 16, 2024 10:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Looks like it's on path to head upward now that it's in the trajectory lines with November through January lows!
Alejandro Pe
Alejandro Pe Dec 08, 2023 9:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good techonology. Matter of time.
Ante Parcina
Ante Parcina Aug 27, 2023 6:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
the most wild share on WallStreet. If they found any significant research in genetics 10$ imidiatly. if not bleed bleed bleed. so if u buy these price with 10k$ or go to few thousands or make 100k$ in year!!!
MIKHAIL KUZNETSOV
MIKHAIL KUZNETSOV Jan 30, 2022 8:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Against the background of the upcoming catalysts, $ 5.7 was added, I think we will soon see a race to the north
Avise Analytics
Avise Aug 26, 2021 7:53AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.reddit.com/r/MicrocapStocksRun/comments/pbxwja/3_biotech_stocks_insiders_are_selling/?utm_source=share&utm_medium=web2x&context=3
andrew mccorkle
andrew mccorkle Aug 26, 2021 7:53AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
⁰out living in imperial zzz hcm km
Katona Örs
Katona Örs Jan 26, 2021 3:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What its happening? Why its going so much down?
Thao Bui
Thao Bui Dec 10, 2020 8:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
rocket
Fatma Argün
Fatma Argün Nov 11, 2020 1:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The news about the biontech vaccine is said to be false.
Pavel Galkin
Paul_G Aug 10, 2020 7:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$15 before end of September
Ashish Rajput
Ashish Rajput Aug 10, 2020 7:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
unlikely before next January
Ashish Rajput
Ashish Rajput Apr 08, 2019 11:19AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
see it coming down to $10 level few days
Graydon Britton
Graydon Britton Apr 08, 2019 11:19AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
you got that one right :)
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email